COVID-19 trials registries data warehouse

https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=19319

Lucas Otieno Tina

Itina@vibriafrica.org

2021-12-13

Not recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

To be eligible for the study, each HIV (+) participants must satisfy all of the following criteria: 1. Adolescent male or female aged = 12 to 17 years at screening and adult male or female aged = 18 to 64 years at screening (inclusive). 2. Written informed consent (and assent if adolescent), after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee. For participants who cannot read or write, the consent must be witnessed by a literate third party not involved in study conduct. 3. Comply with study procedures, including potential home visits for COVID-19 follow-up. 4. Has completed a primary homologous vaccination series at least 3 months but no more than 6 months prior to enrollment. Vaccinations allowed include: a) mRNA (Moderna mRNA-1273 or Pfizer/BNT) – primary series is 2 doses b) Adenovector 26 (Janssen Ad26COVS1) – primary series is 1 dose, c) Inactivated whole virus (Sinopharm-BIBP) – primary series is 2 doses, 5. Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [i.e, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or documented plasma follicle-stimulating hormone level =40 mIU/mL]) must agree to consistently use an effective method of contraception from enrolment and agree to continue adequate contraception until 12 weeks after vaccination:a. Condoms (male or female) b. Diaphragm with spermicide c. Cervical cap with spermicide d. Intrauterine device e. Oral or patch contraceptives f. Hormonal Contraceptives implants or injection e.g., Norplant®, Depo-Provera®. g. Abstinence, as a form of contraception, is acceptable if in line with the participant’s lifestyle. NOTE: Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Theseprocedures and laboratory test results must be confirmed by physical examination, by participant recall of specific date and hospital/facility of procedure, or by medical documentation of said procedure.6. Medically stable at screening, as determined by the investigator (based on review of health status, vital signs, medical history, and targeted physical examination). Acceptable Vital signs as determined by the Principal Investigator or designee. 7. Receiving highly active antiretroviral therapy (HAART) and using the same regimen the past 8 weeks before screening. Changes in antiretroviral dosage within 8 weeks prior to entering the study are permitted. In addition, the exchange of pharmacological formulation (e.g., the conventional formulation for combination formulations) is allowed. If regimen has changed then the participant can be reconsidered for inclusion once the 8 weeks has passed. 8. An HIV-1 viral load < 1000 copies/mL and/or CD4 Count = 200 cells/mm3 within 3 months before randomization. May be taken during screening or utilize medical testing from clinic. 9. Documentation of HIV test result by HIV rapid test or assay as per the Ministry of Health guidelines in the respective countries irrespective of HIV status. Each HIV (-) participant must meet all the following criteria to be enrolled in this study: 1. Male or female aged = 18 to 64 years at screening, inclusive. 2. Willing and able to give informed consent prior to study enrolment and co

Participants with any of the following criteria will be excluded: 1. Any ongoing, symptomatic acute illness requiring medical or surgical care or chronic illness of moderate or severe grade including HIV Stage III/IV or chronic illness/disease that is not stable (at the discretion of the investigator). Acute illness is a temporary exclusion for which the participant may be re-evaluated once they improve or recover. 2. Use of a heterologous COVID-19 primary series at the platform level (mRNA, Adenovector and inactivated vaccine). 3. Unstable or Severe Chronic disease inclusive of: a. Hypertension (elevated blood pressure [SBP>155mmHg or DBP>100mmHg]). Note that participants can be retested once after resting or return on another day for retesting. Participants may also have anti-hypertensive medication adjusted and may be reassessed after at least 2 weeks.b. Congestive heart failure (CHF) stage 3 or greater or diagnosed cardiovascular disease that is not controlled using medication in the past 6 months. c. Chronic obstructive pulmonary disease (COPD) with a history of an acute exacerbations repeated in the past 2 years. Note: If participant has been stable the last 6 months and are not Gold stage 3 or greater, they may be included. d. Asthma stage 4 and/or unstable cases with asthma therapy adjustments in the past that 2 months. e. Type 1 or any type 2 diabetes (adult onset) with an HbA1c > 8.5 in the last 6 months. Any participant with diabetes is required to have an AIC value in last 6 months. Adolescents may not be diabetic. f. Chronic kidney disease requiring dialysis or GFR <30 (may use associated creatinine based on age and gender) g. Chronic hepatic disease with evidence of hepatic compromise. Includes known Hepatitis B or C. h. Chronic or serious neurological diseases (e.g. cerebrovascular disease (including transient ischemic attacks), autoimmune disorders, neurologic deterioration (including dementia), Guillain Barre syndrome) 4. Cognitive impairment – congenital or acquired 5. Participation in research involving an investigational product (drug/biologic/device) within 30 days prior to first study vaccination. Exception is if participant in a follow up safety phase and the investigation product has been given > 6months previously. 6. Prior receipt of an Ebola vaccine i.e., Ad26.ZEBOV/MVA-BN-Filo vaccines. 7. Received any other vaccine within 4 weeks prior to first study vaccination or planned vaccination within 2 weeks after study vaccination (exception for mass vaccination campaigns). Participants may be revaluated after the window has passed. 8. Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital), excluding HIV. Note: Stable endocrine disorders that have a confirmed autoimmune etiology (e.g., thyroid, pancreatic), including stable diabetes are allowed. 9. Chronic administration (>14 continuous days) of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 60 days prior to first study vaccination, excluding HAART. Note: An immunosuppressant dose of glucocorticoid is defined as a systemic dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.10. Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination, excluding HAART. 11. Temporary exclusion: Acute respiratory and/or non-respiratory illness consistent with po

6

Victoria Biomedical Research Institute

12

64

Kenya;Congo;Rwanda

Healthy volunteers

N/A

1950

To evaluate Serious Adverse events related to vaccination of Ad26.COV2S1 or NVX-CoV2372 during the entire study.;To evaluate the immunogenicity of Ad26.COV2S1 and NVX-CoV2372 vaccines at day 28; To evaluate reactogenicity (solicited adverse events (AEs) Ad26.COV2S1 and NVX-CoV2372 following boosting.

| Declared number of arm (6.0) differs from found arms (7.0)

Phase 2

[{"arm_notes": "Homologous, HIV +", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Homologous, HIV -", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Homologous, HIV +", "treatment_id": 918, "treatment_name": "Nvx-cov2373", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Homologous, HIV -", "treatment_id": 918, "treatment_name": "Nvx-cov2373", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Heterologous", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Heterologous", "treatment_id": 918, "treatment_name": "Nvx-cov2373", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]